Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.54B P/E - EPS this Y - Ern Qtrly Grth -
Income -125.42M Forward P/E - EPS next Y - 50D Avg Chg -2.00%
Sales 484.85M PEG - EPS past 5Y - 200D Avg Chg -5.00%
Dividend N/A Price/Book 1.33 EPS next 5Y - 52W High Chg -16.00%
Recommedations - Quick Ratio 8.53 Shares Outstanding 65.65M 52W Low Chg 11.00%
Insider Own 25.64% ROA -1.79% Shares Float 40.32M Beta 0.30
Inst Own 26.91% ROE -4.72% Shares Shorted/Prior -/- Price 53.75
Gross Margin -1.75% Profit Margin -21.29% Avg. Volume 6 Target Price -
Oper. Margin -32.23% Earnings Date - Volume 47 Change 0.00%
GALAPAGOS NV News
08/08/22 Galapagos receives transparency notification from FMR LLC
08/04/22 First key steps in pipeline rebuild and strong commercial progress in H1 2022
06/29/22 Are Medical Stocks Lagging Galapagos (GLPG) This Year?
06/22/22 Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field
06/21/22 Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
06/20/22 Galapagos increases share capital through subscription right exercises
06/09/22 Wall Street Analysts See a 28% Upside in Galapagos NV (GLPG): Can the Stock Really Move This High?
06/02/22 Is Galapagos (GLPG) Stock Outpacing Its Medical Peers This Year?
05/25/22 Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
05/24/22 Galapagos In-licenses Inflammatory Bowel Disease Drug Targets From Scipher Medicine
05/16/22 Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?
05/11/22 Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs
05/09/22 RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value
05/06/22 Galapagos creates new subscription right plans
05/05/22 Galapagos demonstrates regulatory and commercial progress in Q1 2022
04/28/22 Has Galapagos (GLPG) Outpaced Other Medical Stocks This Year?
04/26/22 Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board
04/04/22 Strength Seen in Galapagos NV (GLPG): Can Its 5% Jump Turn into More Strength?
03/28/22 Jyseleca® approved in Japan for ulcerative colitis

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.